Global Blood Cancer Drugs Market Report, History and Forecast 2018-2034, Breakdown Data by Companies, Key Regions, Types and Application
Published on: 2024-01-04 | No of Pages : 400 | Industry : Pharma & Healthcare
Publisher : MRA | Format : PDF
Global Blood Cancer Drugs Market Report, History and Forecast 2018-2034, Breakdown Data by Companies, Key Regions, Types and Application
Blood cancers, or hematologic cancers, affect the production and function of blood cells. Most of these cancers start in the bone marrow where blood is produced.
Blood Cancer Drugs report published by QYResearch reveals that COVID-19 and Russia-Ukraine War impacted the market dually in 2022. Global Blood Cancer Drugs market is projected to reach US$ 91940 million in 2034, increasing from US$ 62740 million in 2022, with the CAGR of 5.5% during the period of 2024 to 2034. Demand from Leukemia and lymphoma are the major drivers for the industry.
North America, Europe and Asia Pacific are the key regions for Blood Cancer Drugs industry. Among those areas, stimulated by rigid demand from downstream industries, Asia Pacific is estimated to experience fast growth, with the CAGR of % during 2024 to 2034.
Globally, Blood Cancer Drugs key companies include Amgen,, AstraZeneca PLC,, Astellas Pharma,, Bayer AG,, Bristol-Myers Squibb Company,, Celgene Corporation,, Eli Lilly,, F.Hoffmann-La Roche, and Johnson & Johnson,, etc. Amgen,, AstraZeneca PLC,, Astellas Pharma, are top 3 players and held % share in total in 2022.
Blood Cancer Drugs can be divided into Blood Chemotherapy Drugs and Blood Targeted Therapy Drugs, etc. Blood Chemotherapy Drugs is the mainstream product in the market, accounting for % share globally in 2022.
Blood Cancer Drugs is widely used in various fields, such as Leukemia, lymphoma and Multiple Myeloma,, etc. Leukemia provides greatest supports to the Blood Cancer Drugs industry development. In 2022, global % share of Blood Cancer Drugs went into Leukemia filed.
Report Scope
This report, based on historical analysis (2018-2022) and forecast calculation (2024-2034), aims to help readers to get a comprehensive understanding of global Blood Cancer Drugs market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.
Companies, Type, Application and Regions Listed in the Report
Amgen,
AstraZeneca PLC,
Astellas Pharma,
Bayer AG,
Bristol-Myers Squibb Company,
Celgene Corporation,
Eli Lilly,
F.Hoffmann-La Roche,
Johnson & Johnson,
Novartis
Pfizer,
Takeda Pharmaceutical Company Ltd,
AbbVie
Segment by Type
Blood Chemotherapy Drugs
Blood Targeted Therapy Drugs
Leukemia
lymphoma
Multiple Myeloma
By Region
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Nordic Countries
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Latin America
Mexico
Brazil
Middle East & Africa
Turkey
Saudi Arabia
UAE
Each chapter of the report provides detailed information for readers to understand the Blood Cancer Drugs market further
Chapter 1Global and regional market size and CAGR for the history and forecast period (2018-2024, 2024-2034).
Chapter 2Product Types and Revenue analysis of Each Type in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa from 2018 to 2024.
Chapter 3Product Application and Revenue analysis of Each Application in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa from 2018 to 2024.
Chapter 4Company Competition Status, Detailed analysis of Product Name companies’ competitive landscape, revenue, market share and ranking, latest development plan, merger, and acquisition information, etc.
Chapter 5Companies’ Outline, covering company’s basic information, Blood Cancer Drugs introduction, etc. Blood Cancer Drugs Revenue and Gross Margin of each company as well as Recent Development are also contained in this part.
Chapter 6 to 10Country Level analysis of North America, Europe, Asia-Pacific, Latin America, Middle East and Africa by revenue.
Chapter 11Market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry.
Chapter 12QYResearch’s Conclusions of Blood Cancer Drugs market based on comprehensive survey.
Chapter 13Methodology and Data Sources adopted by QYResearch.
Blood Cancer Drugs report published by QYResearch reveals that COVID-19 and Russia-Ukraine War impacted the market dually in 2022. Global Blood Cancer Drugs market is projected to reach US$ 91940 million in 2034, increasing from US$ 62740 million in 2022, with the CAGR of 5.5% during the period of 2024 to 2034. Demand from Leukemia and lymphoma are the major drivers for the industry.
North America, Europe and Asia Pacific are the key regions for Blood Cancer Drugs industry. Among those areas, stimulated by rigid demand from downstream industries, Asia Pacific is estimated to experience fast growth, with the CAGR of % during 2024 to 2034.
Globally, Blood Cancer Drugs key companies include Amgen,, AstraZeneca PLC,, Astellas Pharma,, Bayer AG,, Bristol-Myers Squibb Company,, Celgene Corporation,, Eli Lilly,, F.Hoffmann-La Roche, and Johnson & Johnson,, etc. Amgen,, AstraZeneca PLC,, Astellas Pharma, are top 3 players and held % share in total in 2022.
Blood Cancer Drugs can be divided into Blood Chemotherapy Drugs and Blood Targeted Therapy Drugs, etc. Blood Chemotherapy Drugs is the mainstream product in the market, accounting for % share globally in 2022.
Blood Cancer Drugs is widely used in various fields, such as Leukemia, lymphoma and Multiple Myeloma,, etc. Leukemia provides greatest supports to the Blood Cancer Drugs industry development. In 2022, global % share of Blood Cancer Drugs went into Leukemia filed.
Report Scope
This report, based on historical analysis (2018-2022) and forecast calculation (2024-2034), aims to help readers to get a comprehensive understanding of global Blood Cancer Drugs market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.
Companies, Type, Application and Regions Listed in the Report
By Company
Amgen,
AstraZeneca PLC,
Astellas Pharma,
Bayer AG,
Bristol-Myers Squibb Company,
Celgene Corporation,
Eli Lilly,
F.Hoffmann-La Roche,
Johnson & Johnson,
Novartis
Pfizer,
Takeda Pharmaceutical Company Ltd,
AbbVie
Segment by Type
Blood Chemotherapy Drugs
Blood Targeted Therapy Drugs
Segment by Application
Leukemia
lymphoma
Multiple Myeloma
By Region
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Nordic Countries
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Latin America
Mexico
Brazil
Middle East & Africa
Turkey
Saudi Arabia
UAE
Each chapter of the report provides detailed information for readers to understand the Blood Cancer Drugs market further
Chapter 1Global and regional market size and CAGR for the history and forecast period (2018-2024, 2024-2034).
Chapter 2Product Types and Revenue analysis of Each Type in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa from 2018 to 2024.
Chapter 3Product Application and Revenue analysis of Each Application in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa from 2018 to 2024.
Chapter 4Company Competition Status, Detailed analysis of Product Name companies’ competitive landscape, revenue, market share and ranking, latest development plan, merger, and acquisition information, etc.
Chapter 5Companies’ Outline, covering company’s basic information, Blood Cancer Drugs introduction, etc. Blood Cancer Drugs Revenue and Gross Margin of each company as well as Recent Development are also contained in this part.
Chapter 6 to 10Country Level analysis of North America, Europe, Asia-Pacific, Latin America, Middle East and Africa by revenue.
Chapter 11Market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry.
Chapter 12QYResearch’s Conclusions of Blood Cancer Drugs market based on comprehensive survey.
Chapter 13Methodology and Data Sources adopted by QYResearch.
Electronic and Semiconductor
Food and Beverages
Chemicals and Materials
Consumer Goods
Construction Manufacturing
Aerospace and Defence
Energy and Power
ICT Media
Banking and Finance
Automotive and Transportation
Machinery and Equipments
Pharmaceutical and Healthcare
Medical Devices